Altimmune
ALT
103 hedge funds and large institutions have $207M invested in Altimmune in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 19 closing their positions.
832% more call options, than puts
Call options by funds: $4.98M | Put options by funds: $534K
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
1% more funds holding
Funds holding: 102 → 103 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.85% less ownership
Funds ownership: 81.71% → 77.86% (-3.8%)
30% less capital invested
Capital invested by funds: $296M → $207M (-$88.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$7.17M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$6.99M |
| 3 |
VA
VR Adviser
New York
|
+$5.59M |
| 4 |
Millennium Management
New York
|
+$4.33M |
| 5 |
ACM
Altium Capital Management
New York
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$27.5M |
| 2 |
Rafferty Asset Management
New York
|
-$3.33M |
| 3 |
Citigroup
New York
|
-$2.03M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.57M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.49M |
ALT Hedge Fund Activity: Q1 2022 in Review
103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2022, worth a combined $207M — down 30% from $296M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ALT positions and 19 closed out — a net gain of 1 holder — while 35 added to existing stakes and 31 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $7.17M. The largest seller was State Street, cutting an estimated $27.5M.
- 103 institutional investors held Altimmune (ALT) as of Q1 2022, up from 102 in Q4 2021.
- Funds reported $207M of Altimmune stock for Q1 2022, down 30% quarter-over-quarter.
- 20 funds opened new Altimmune positions in Q1 2022 and 19 closed out, a net change of +1 holder.
- The largest Altimmune buyer in Q1 2022 was Tang Capital Management, an estimated $7.17M added.
- The largest Altimmune seller in Q1 2022 was State Street, an estimated $27.5M sold.
Based on aggregated 13F filings for Q1 2022.